BACKGROUND: Medicare Part D provides insurance coverage for prescription drugs to elderly and disabled consumers. Part D accounted for 24% of prescriptions dispensed by independent pharmacies in the first year of the program (2006). To date, the impact of Part D on independent pharmacies has been explored only in small, qualitative, or non-peer-reviewed studies.
T he Medicare Part D prescription drug program was implemented on January 1, 2006. Part D was intended to fill a major gap in the Medicare program by providing insurance coverage for prescription drugs to elderly and disabled consumers, many of whom would otherwise lack coverage. The literature, while providing widely varying estimates, indicates that Part D has been successful in providing prescription drug insurance to many elderly consumers who would otherwise not be insured. 
What is already known about this subject
What this study adds
• Part D was associated with an absolute 0.7% decline in the typical independent pharmacy's gross margin percent for prescriptions.
• In 2006, Part D induced an estimated increase in utilization of 427 prescriptions among Part D enrollees at the typical independent pharmacy. However, 229 prescriptions were lost to mail order.
• Part D has decreased the net income of the typical independent pharmacy by a mean (SD) 22% (4%), primarily due to lower reimbursement rates.
survey of 16,000 elderly Medicare beneficiaries, estimate that one-third of elderly consumers lacked drug coverage in 2005 and that 61% of these enrolled in Part D plans in 2006. 1 When these results are extrapolated to the U.S. elderly population (37 million in 2005 2 ), about 7.5 million elderly consumers gained drug coverage as a result of Part D. IMS Health (IMS), based on information from its proprietary database of over 5,400 commercial and Medicare plans, estimates that 3.4 million consumers gained access to drug coverage as a result of Part D during 2006. 3 The Kaiser Family Foundation reports that 23.9 million consumers were enrolled in Part D plans as of January 2007. 4 Early estimates indicate that Part D has increased prescription drug utilization only moderately. Yin et al. report that among patients of a large, national, chain pharmacy, Part D-related average monthly utilization increased 1.1% in the first 5 months of the program and 5.9% in the next 10 months. 5 IMS reports that total utilization (utilization due to Part D and all other effects) among Part D beneficiaries increased by 3% for patients formerly on Medicaid, 10% for those formerly enrolled in private thirdparty plans, and by 26% for those with no prior insurance for prescription drugs. 3 Part of the reason for the small increase in utilization may be that most Part D recipients had insurance for prescription drugs prior to enrolling in Part D. While the 26% increase in prescription drug utilization for the group with no prior drug insurance was substantial, IMS indicates that only 14% of Part D enrollees paid for their drugs entirely out of pocket in the year before enrolling in Part D. A total of 58% previously had private third-party coverage for prescriptions and 24% were covered by Medicaid. The remaining 4% had drug coverage from multiple sources during the year. 3 Because of its effects on prescription sales and reimbursement, Part D could have a major impact on the profitability of community pharmacies in at least 3 ways. First, the limited evidence available to date suggests that Part D is likely to result in lower gross profit margins on prescriptions dispensed in community pharmacies. [6] [7] [8] [9] (The gross profit on a prescription is the difference between the amount the pharmacy is reimbursed for a prescription and the amount the pharmacy paid for the drug product dispensed. The gross profit margin is the gross profit divided by the amount the pharmacy was reimbursed and multiplied by 100.) Because most Part D beneficiaries had prescription drug coverage prior to their Part D enrollment, many prescriptions that previously were reimbursed out-of-pocket (cash), by private thirdparty plans, or by Medicaid are now covered by Part D plans. Gross margins on prescriptions reimbursed by Medicaid, cash, or by private third parties typically yield higher margins than those reimbursed by Part D. 6, 7 For example, the 2007 National Community Pharmacist Association (NCPA) NCPA-Pfizer Digest estimates gross margins of 19.6% for Medicaid prescriptions, 18.5% for private third-party prescriptions, and 16% for prescriptions reimbursed by Part D. 7 Thus, the change to Part D payment for prescriptions that were previously, or would otherwise have been, reimbursed by cash, Medicaid, or private third-party insurance results in a lower gross margin for the pharmacy. Second, providing prescription drug insurance to patients who would otherwise be uninsured should increase the total volume of prescriptions dispensed. All else equal, this change should increase community pharmacies' prescription sales. Third, Part D may induce a shift of prescription volume from community pharmacies to mail-order pharmacies. This shift would occur because Part D plans, like most private third-party programs, usually offer consumers substantial financial incentives to have maintenance prescriptions dispensed through mail-order pharmacies. [10] [11] [12] For example, many third-party payers offer patients a 90-day supply of medication through the mail-order pharmacy for the equivalent of two 30-day supply copayments. Thus, the patient pays 33% less by using the mail-order pharmacy.
A few studies have examined the effects of Part D on community pharmacies. The Office of the Inspector General (OIG) compared pharmacy reimbursement for Part D prescriptions with pharmacies' drug acquisition costs. 13 The study found that Part D reimbursement for product acquisition costs exceeded actual pharmacy acquisition costs by an average of $9.13 (or 18.1%) per prescription. In addition, Part D paid pharmacies an average dispensing fee of $2.27. This total reimbursement amount represented an average gross margin of $11.40, or 18.4%, for Part D prescriptions. Self-reported estimates from 69 of the 99 sampled pharmacies indicated average dispensing costs of $9.13 (range $3.50 to $19.00) per prescription. OIG reports that the estimates were based on different methods and that it "was unable to assess the accuracy of those estimates."
The OIG study also found that Part D dispensing fees were about $2 less, on average, than those paid by Medicaid. This difference in dispensing fees could partially explain why Part D margins are lower than those paid by Medicaid. However, to fully understand the difference in gross margins, it would be necessary to also know how Medicaid product reimbursement compares with Part D product reimbursement. The OIG study did not examine the effect of Part D on pharmacy sales or the difference between reimbursement and acquisition costs for prescriptions reimbursed by other payers. As a result, the report provided an incomplete picture of the effect of Part D on community pharmacies' profitability.
Radford et al. examined independent pharmacists' early (first 7 post-implementation months) experiences with Part D using semi-structured telephone interviews conducted with 22 rural pharmacies located in 10 states.
14 Their interviews suggested that gross margins have decreased, prescription volume has increased, but prescription sales have remained flat. However, this study provided qualitative results based on pharmacists' impressions and opinions rather than specifically measuring Part D's effects on pharmacy profitability through examination of financial records.
A report posted on the website of the Center for Pharmaceutical Marketing and Management at the University of Mississippi details the results of Reisetter et al.'s study of the effects of Part D on the profits of community pharmacies. 9 The study compared 300 pairs of matched prescriptions from 10 pharmacies located throughout the United States. One prescription from each pair was reimbursed by Part D in 2006; the matching prescription was for the same product and quantity, but reimbursed by cash, Medicaid, or a private third-party plan in 2005. The authors estimated Part D gross margins at 18.6% compared with 24.0% for prescriptions reimbursed by a combination of cash, Medicaid, and private third-party plans, and concluded that the decline in gross margin resulting from Part D implementation would decrease the net income of the typical community pharmacy by 21%. The study was limited in that it was based on a small sample of prescriptions from 10 pharmacies. Further, the analysis did not consider potential changes in prescription volume due to increased insurance coverage and mail-order usage.
Winegar and colleagues examined changes in gross margins when prescriptions switched from Medicaid to Part D coverage. 8 Their results were based on data taken from a sample of 313 independent pharmacies in Texas. After adjusting for inflation, the average gross margin fell from 26. There are at least 2 reasons that managed care organizations should be interested in the financial viability of independent pharmacies. First, over the last several years, the growth of Medicaid managed care and the implementation of Medicare Part D have substantially increased the number of managed care patients living in rural and inner city areas. Independent pharmacies are more likely to be located in these areas. ShambaughMiller et al. note, for example, that in 2007, 2,019 independent pharmacies were the only pharmacies in their community. Of these, 1,044 were located at least 10 miles from the next nearest pharmacy. 15 In order to provide rural and inner-city patients with convenient access and adequate pharmacy services, managed care organizations need both urban and rural pharmacies in their networks. Second, managed care organizations' ability to negotiate discounts on reimbursement rates with pharmacies depends on the number of pharmacies in a market area; as the number of pharmacies declines, so too does the ability of managed care organizations to negotiate discounts.
■■ Objective
The purpose of this study was to provide a preliminary estimate of the effects of Medicare Part D on the profitability of independent community pharmacies.
Estimating the Impact of Medicare Part D on the Profitability of Independent Community Pharmacies
■■ Methods A financial model was constructed to predict the impact of the Medicare Part D program on independent community pharmacies' profitability. Stahl suggests that models are used when research based on primary data collection or direct observation is not feasible, in order to better understand or predict the system or phenomena under study, and in order to aid decision making. 16 Based on these considerations, estimating the impact of Part D seems well suited to a modeling approach.
Using research based on primary data collection to study the impact of Part D on pharmacy profits would be extremely difficult. Because almost all pharmacies participate in Part D, it would be difficult, if not impossible, to find an adequate control group. Measuring the effects of Part D using a pre-post design without a control group would provide results that were confounded by changes in the environment, including changes in reimbursement rates of other third-party payers, changes in sales caused by factors other than Part D, changes in the ratio of brand-name to generic drug sales, and changes in competition such as the Wal-Mart $4 generic program. While it would be possible to examine certain aspects of Part D's effects on community pharmacies, as has been done by the OIG, 13 Radford et al., 14 Reisetter et al., 9 and Winegar et al., 8 it would be much more difficult to design a study that examined all of the major effects of Part D.
A model, by comparison, is able to make estimates that are free of the effects of confounding variables by varying only those variables that are affected by Part D. In addition, a model is able to take data from disparate sources and use them in a single, comprehensive analysis. A model is also useful because it explores and explains relationships in the system. 17 The model used in this study, for example, examines and quantifies the relationships between changes in profits and changes in reimbursement rates, increases in prescription sales, and increases in mail-order usage. The model shows how these components relate to each other and the magnitude of the impact of each change on pharmacy profit.
Model Overview
The model estimated the impact of Medicare Part D on the profitability of a typical independent pharmacy using non-peerreviewed data sources, which were the only data sources currently available. First, key financial metrics (sales, cost of goods sold, operating expenses, number of prescriptions dispensed, and average price per prescription) were drawn from NCPA survey data for 2005, the year prior to Part D implementation. Payer mix for 2005-the percentage of prescriptions attributable to each of 3 payer sources (Medicaid, private third-party insurance, and out-of-pocket spending by individuals with no prescription coverage)-was also derived from the NCPA survey. Second, IMS national market share data were used to estimate rates of conversion from the other 3 payment sources to Medicare Part D. The estimated changes in market share after Part D implementation were calculated by applying the conversion rates to the 2005 market share percentages. Third, IMS market share data and other sources were used to estimate other changes in utilization associated with Part D, including both increases in utilization associated with Part D coverage and decreases in community pharmacy sales associated with shifts to mail-order pharmacy use. Fourth, the gross margins for each payer type were applied to the market share data to calculate a new overall gross margin. Finally, the changes in gross margin and utilization were applied to the typical independent pharmacy's income statement for 2005 to estimate net profit for 2006. (Table 1) ; percent of prescriptions dispensed by payer for Medicaid, private third-party payers, and cash (Table 2) ; and gross margin percentages by payer (Table 3) . Data for the Digest were collected by an annual survey of the owners of independent pharmacies that had been in business for at least 1 complete year. All pharmacies in the sample were "pharmacist-owned, privately held businesses." 6 The sample may include, in addition to traditional single-store community pharmacies, long-term care, specialty, and compounding pharmacies. The sample may also include independent pharmacies that are franchise operations or that are located in supermarkets. Owners were asked to complete and submit a questionnaire covering demographic and non-financial information and to complete forms that provided balance sheet and income statement information. Much of the data in the Digest-such as prescription and other sales, gross margins, and expenses-were calculated directly from the financial information provided. However, some data-such as estimates of prescription volume and gross margins by payer-were based on owners' estimates. The extent to which owners based these estimates on data or judgment is not known.
Data Sources
Medicare Part D-The First Year (IMS) included estimates of the rates of conversion of prescriptions to Part D payment by previous payer and of increases in utilization for Part D patients by prior payer (Table 2) . 3 The IMS report was based on information from a proprietary database covering over 5,400 commercial and Medicare health plans. IMS data were based on prescriptions dispensed in both community and mail-order pharmacies.
As discussed earlier, the model assumed that Part D affected the profitability of community pharmacies in 3 ways: (a) increasing sales by providing drug insurance to previously uninsured patients, (b) decreasing sales by inducing patients to use mailorder pharmacies, and (c) decreasing gross margin. The estimation of each of these effects is discussed below.
Estimation of Increased Prescription Utilization Due To Insurance
The number of new prescriptions that patients purchased as a result of Part D was estimated as the product of the number of prescriptions converted from other payers to Part D and the post-Part D increases in utilization by previous payer ( Change in share = (original share for payer × conversion rate) + (original share for payer × conversion rate × increased utilization rate). 72.0 -65.9 = (72.0 × conversion rate) + (72.0 × conversion rate × 0.10).
Conversion rate = 7.7%
After removing the changes due to increased utilization, the conversion rates (that is, the percentage of prescriptions by payer converted to Part D) were 44.6% for Medicaid prescriptions, 7.7% for private third-party prescriptions and 7.3% for cash prescriptions.
These figures could not be entered directly into the present study's model because the sample of pharmacies in the IMS report included all types of community pharmacies (chain, independent, food store) as well as mail-order pharmacies. To the extent that independent pharmacies serve a higher proportion of older patients than do other types of community pharmacies, more of the independent pharmacies' patients will be eligible for Part D. Consequently, the conversion rate of cash, Medicaid, and private third-party prescriptions to Part D payment may be higher in independent pharmacies than in the IMS sample. NCPA 7 and IMS 3 estimates of the proportions of prescriptions reimbursed by Part D provide support for this hypothesis. The IMS report indicates that 14.6% of prescriptions in all community and mailorder pharmacies were reimbursed by Part D in 2006. 3 The NCPA Digest-which includes only independent pharmacies-indicates that, for the same time period, 24% of prescriptions were reimbursed by Part D. Applying the IMS conversion rates to the 2005 NCPA market share data would have resulted in an estimated market share percentage of approximately 16% for Part D. To account for the higher rate of conversions in independent pharmacies, the conversion rates reported by IMS were increased by 45 percent so that the percentage of prescriptions reimbursed by Part D as estimated in the model was 23.7%, approximately equal to the rate of 24% that was reported in the 2007 NCPA Digest. The conversion rates used in the study, reflecting the 45% adjustment, were 64.7% for Medicaid prescriptions, 11.2% for private third-party prescriptions, and 10.5% for cash prescriptions (Table 3) . A sensitivity analysis examined the effects of varying conversion rates by 25% above and below these figures.
The IMS report provides estimates of increases in total utilization by previous payer. 3 For example, Part D recipients who previously paid cash used 26% more prescriptions in 2006 than in 2005. The number of prescriptions dispensed annually has been increasing for many years. 18 Consequently, it is unreasonable to assume that the total increase in utilization from 5 These data yield an approximate 3.9% increase for the year. These results were based on data from a national chain pharmacy. Given that about 14.6% of all prescriptions were reimbursed by Part D in 2006 according to IMS data, 3 a 3.9% increase in utilization among Part D eligible patients would equate to about a 0.57% increase in total prescription volume. A 5.9% increase for Part D patients would yield a 0.86% increase in total volume. Given this range, a sensitivity analysis in the present study examined the effects on pharmacy profitability of Part D-related increases in prescription volume from 0%-1% of total prescription volume. 10, 19 The information in the Takeda reports is based on a national survey of benefit managers in employersponsored health plans.
Estimation of Decreased Prescription Volume Due to Mail-Order
IMS Health indicates that 22% of all non-institutional prescription sales 18 and 7% of all non-institutional prescriptions 20 were dispensed through mail-order pharmacies in 2006. (Noninstitutional prescriptions refer to those dispensed in chain and independent pharmacies, food store pharmacies, and mail-order pharmacies; they do not include prescriptions dispensed in clinics, health maintenance organizations, hospitals, federal facilities, long-term care facility pharmacies, or by home health agencies.) Given that mail-order prescriptions are typically for 90-day supplies, and community pharmacy prescriptions are typically for 30-day supplies, 21 it seems likely that each mail-order prescription in the IMS data would be comparable to 3 community pharmacy (30-day) prescriptions. The fact that IMS's estimates of mail-order prescription dollar sales were about 3 times higher than the estimate of numbers of mail-order prescriptions supports this hypothesis.
The estimate needed in the model was the percentage of noninstitutional prescriptions dispensed by mail-order pharmacies 20 Given these assumptions, it was estimated that mail order dispensed (22%/72% =) 30% of non-institutional, third-party plan prescriptions (30-day equivalents).
Based on these estimates, the model initially assumed that 20% of prescriptions dispensed for patients formerly paying cash or covered by private third parties would be dispensed through mail-order pharmacies. The figure was varied from 10% to 35% in a sensitivity analysis.
The model assumed that the extent of increased mail-order use would differ according to the patients' source of payment prior to Part D. The financial incentive to use mail-order pharmacy usually takes the form of lower patient copayments. Copayments for low-income patients, such as those on Medicaid, are substantially lower than those for patients with higher incomes. 12 Because copayments are lower, the financial incentives to use mail-order pharmacy would be correspondingly weaker. 22 Further, patients enrolled in both Medicaid and Medicare ("dual-eligibles") can change Medicare Part D plans every 30 days. 23 Because of this policy, plans may be reluctant to allow these patients to obtain 90-day supplies of medications. Recent research based on data from the Medical Expenditure Panel Survey documents low use of mail-order pharmacies by patients with public insurance. 22 As a result, the model assumed that no prescriptions for Medicaid patients would be dispensed through mail-order pharmacies.
A community pharmacy would be expected to lose the largest proportion of prescriptions to mail-order pharmacy for those Part D patients who previously paid cash. Prior to Part D, few, if any, of these patients' prescriptions would be dispensed through mail-order pharmacies. 22 After Part D, all of these patients' prescriptions would be subject to dispensing through the mail. Thus, the model assumed that 20% of all prescriptions for Part D patients who previously paid cash would be dispensed through mail-order pharmacies. This assumption was based on the rate of 20% of all third-party prescriptions being dispensed through the mail that was discussed earlier.
A community pharmacy would be expected to experience a smaller shift of prescriptions to mail-order for Part D patients whose prescriptions were previously reimbursed by private third-party programs. These patients would have been subject to strong financial incentives to use mail-order pharmacy prior to being covered by Part D. As a result, the model assumed that any prescriptions that they chose to have dispensed in a community pharmacy before implementation of Part D would continue to be filled in a community pharmacy after implementation of Part D. However, any new prescriptions dispensed as a result of Part D coverage would be subject to dispensing through mail-order. Therefore, the model estimated community pharmacies' loss of prescriptions to mail-order pharmacy from these patients to be 20% of any new prescription volume resulting from Part D coverage.
To sum up, the number of prescriptions lost to mail-order as a result of Part D was estimated as 20% of all Part D prescriptions dispensed for patients who previously paid out-of-pocket and 20% of new, Part D-induced prescriptions for patients who previously had private third-party coverage ( Table 2) .
Estimation of Change in Prescription Gross Margin Percentage
A pharmacy's prescription gross margin percentage is determined by the relative proportion of prescriptions reimbursed by each payer-cash, Medicaid, private third-party plans, Part D-and the average gross margin percent earned on prescriptions reimbursed by each payer. To estimate the change in the typical community pharmacy's gross margin percentage, the model first estimated the change in the percentage of prescriptions covered by each payer after implementation of Medicare Part D (Tables 2 and 3) .
The model initially used a gross margin percent of 18.5% for Part D prescriptions. This approximates the gross margins estimated in studies by the OIG 13 and Reisetter et al. 9 A sensitivity analysis examined the effects of varying the gross margin paid by Part D plans from 16% to 21%. The lower margin-16%-is the margin reported in the 2007 NCPA-Pfizer Digest for Part D prescriptions; 7 the higher margin-21%-is slightly above that estimated by Winegar et al. 8 The typical community independent pharmacy's prescription gross margin percentage, after implementation of Medicare Part D, was then calculated as the average of the gross margins earned from each payer weighted by the proportion of the pharmacy's prescription volume represented by each payer (Table 3) .
Estimation of Overall Effect on Profitability
The average prescription price after implementation of Part D was estimated based on the new gross margin percentage, assuming no change to the per-prescription cost of goods sold (Table 4) . Post-implementation prescription volume (number of prescriptions) was calculated as pre-implementation (2005) prescription volume plus the Part D-induced increase in prescription volume less the Part D-induced loss of prescriptions to mail-order pharmacies (Tables 2 and 4 ). Post-implementation prescription sales were estimated as post-implementation prescription volume multiplied by post-implementation average prescription price (Table 4) . Post-implementation cost of goods sold was estimated as post-implementation prescription volume multiplied by the average per-prescription cost of goods sold (which was assumed to be the same both pre-and post-implementation; Table 4 ). The model assumed no Part D-related change in operating expenses.
Sensitivity Analysis
One-way sensitivity analyses were used to determine the extent to which uncertainty in individual variables affected the final estimate from the model. Probabilistic sensitivity analyses were used to consider the effects of uncertainty in multiple variables simultaneously and to incorporate the probabilities associated with the uncertainty in each variable. One-way sensitivity analyses examined the effects of assumptions about gross margin, rates of conversion to Part D from other reimbursement sources, change in total prescription volume related to Part D, and the mail-order conversion rate, using the input values shown in Table 5 . The variables, values, and probabilities used in the probabilistic sensitivity analysis are shown in Table 6 . The probabilistic sensitivity analysis was conducted using a Monte Carlo simulation with 1,000 iterations using Microsoft Excel 2003 (Microsoft, Redmond, Washington, 2003).
■■ Results
The model estimated that 23.7% of prescriptions dispensed by the typical independent community pharmacy were reimbursed by Medicare Part D in 2006 (Tables 2 and 3 ). The vast majority of these prescriptions would have otherwise been reimbursed by Medicaid, private third-party plans, or cash. The change in payer mix, combined with the lower gross margin on Part D prescriptions, resulted in an estimated decrease in the typical independent community pharmacy's gross margin from 22.7% in the year before implementation of Part D to 22.0% in the year following implementation (Table 3) .
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Calculation of Average Prescription Price, Prescription Sales, and Prescription Cost of Goods Sold After Part D Implementation
Post-Implementation Average Prescription Price
The model estimated that implementation of Part D resulted in covered patients using an additional 427 prescriptions (Table 2) . However, an estimated 229 prescriptions converted to or induced by Part D that otherwise would have been dispensed by the community pharmacy were instead dispensed through mail-order pharmacies. Thus, the typical independent community pharmacy's net Part D-induced increase in volume was 198 prescriptions per year. The typical pharmacy's estimated total prescription volume after Part D was 52,550. Thus, Part D induced an increase in prescription volume of 0.38% (198/52,353) .
As a result of the effect of the decreased gross margin for Part D prescriptions, along with the small net increase in prescription sales, the typical pharmacy's estimated prescription sales decreased by $18,647, from $3,210,239 to $3,191,592, as a result of Medicare Part D (Table 1 ). The pharmacy's cost of goods sold increased by $9,154 as a result of dispensing an additional 198 prescriptions. The net effect was a decrease of $27,801, or 21.6%, in the pharmacy's pretax net income. Thus, lower reimbursement rates from Part D plans had a much greater effect on pharmacy profits than did either the increase in utilization resulting from increased insurance coverage or the change in use of mail-order pharmacies.
Sensitivity Analysis
The results of one-way sensitivity analyses are shown in Table 5 . Within the ranges tested, the factor with the greatest effect on profitability was the gross margin earned on The model also indicated that increased use of mail-order pharmacies did not have a major impact on community pharmacy profits. This outcome was likely a result of several factors: low use of mail-order pharmacies among Medicaid patients, the small effect of Part D in inducing new prescription use, and the relatively small number of previously cash-paying patients that enrolled in Part D.
The factor having the greatest impact on pharmacy profitability was the decrease in gross margin from lower Part D reimbursement rates. This outcome occurred because the great majority of prescriptions dispensed for Part D, over 98% based on the estimates in Table 2 , would have been reimbursed by other payers at higher gross margins had Part D not been implemented.
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Sensitivity analyses revealed no scenario-over the ranges tested-in which net profit increased as a result of Part D. Even the best-case scenario produced a small negative effect on net profit. Model results were not sensitive, over the ranges tested, to the rate of mail-order prescription use, the rate at which prescriptions were converted to Part D from other payers, or increased utilization induced by Part D coverage. The insensitivity to mail-order usage was probably a result of the small increase in prescription volume related to Part D and the low rate of conversion of cash to Part D prescriptions. Because estimated volume increased only minimally, even Part D mail-order usage of 35% would have small effects on profitability.
The model was much more sensitive to variations in Part D reimbursement rates. Each 1 percentage point decrease in the gross margin earned on Part D prescriptions decreased the pharmacy's profit by about $9,600 per year ( Table 5 ). The trend in pharmacy reimbursement in private plans has been negative over the past decade. 10 The results of this analysis suggest increasing pressure on pharmacy profits from Part D in the future.
While the results indicated that the typical pharmacy suffered a substantial reduction in profits as a result of Part D, they also indicated that the loss was not large enough to put the typical pharmacy out of business in any of the scenarios modeled. However, because no information on the distribution of pharmacies by profitability was available, it was not possible to estimate the number of pharmacies that would be put out of business by Part D.
The model's results apply to the "typical" or "average" independent community pharmacy. Pharmacies with substantial popu lations of elderly patients whose prescriptions were reimbursed by cash or Medicaid before implementation of Part D would have seen much larger negative effects. Pharmacies in rural or inner city areas, which dispense greater proportions of cash and Medicaid prescriptions, would be particularly hard hit by Part D.
The results of the present study also underscore the growing importance to community pharmacies of finding non-product related sources of revenue. Over the last 2 decades, the proportion of prescriptions reimbursed by third-party payers has increased 24, 25 as the rates of reimbursement from these payers have decreased. 10, 26 The conversion of elderly, cash-paying consumers to third-party coverage under Part D was only the latest step in this trend. The trend clearly indicates that dispensing prescriptions will continue to be less and less profitable for community pharmacies, and that the future of community pharmacy lies less in dispensing and more in patient-care services such as medication therapy management.
Limitations
The results of the study are limited in that they are based on a model. To the extent that the data used in the model are not representative, the study may provide misleading results. Most of the data used in the study came from sources that were not peerreviewed (IMS 3 and the NCPA-Pfizer Digest 6 ). Further, estimates of payer mix and gross margins by payer were based on owners' self-reports. It is not known whether these data were based on judgment or actual financial information. Further, the main data sources for the study, IMS and the Digest, provided point estimates of input values without providing measures of error. On the other hand, the data used in the model came from a national sample of 431 independent community pharmacies (as reported in the Digest) and a large, national study of Part D-related changes in prescription use as reported by IMS, a commonly cited reference source. Data from the Digest have been used extensively in studies examining the finances of independent community pharmacies, and IMS is a world-wide leader in the provision of prescription use data. Finally, the model included extensive sensitivity analyses to examine the effects of variations in model inputs.
The model's results are based on a number of assumptions. The major assumptions were based on estimates taken from the literature and were examined in sensitivity analyses. The results were relatively insensitive to variations in all of the parameters examined except Part D reimbursement rates. However, even the most optimistic assumption about Part D reimbursement showed a decrease in the typical pharmacy's net income.
Much of the decrease in profitability associated with Part D resulted from lower gross margins paid by Part D compared with other payers. Part of the difference in gross margins between Part D and other payers could be attributable to different rates of generic drug use, which would lead to different prescription gross margins because pharmacies earn substantially greater margins on generic drugs than on branded drugs. For example, Winegar et al. found gross margins for brand-name drugs of 8.7% for Medicaid and 8.3% for Part D. For generics, margins were 39.9% for Medicaid versus 29.5% for Part D. 8 Data provided in the OIG report indicate gross margins of 8.9% for brands versus 48.0% for generics. 13 (These figures are not reported by OIG but can be calculated from the acquisition cost-reimbursement cost differences and dispensing fees that are reported.) However, the evidence to date indicates that generic usage rates in Part D are similar to, or slightly higher than, those in commercial or Medicaid plans. Winegar et al. indicate that use of generics was not significantly different between Medicaid and Medicare patients in their study. 8 Wolters Kluwer reports that by January, 2007, 63% of Part D claims were dispensed with generics as compared with 59% of private third party plans. 27 The OIG report indicates similar rates of generic drug usage between Part D and Medicaid plans. 13 Thus, it seems unlikely that margin differences between Part D and other payers result from differing rates of generic drug use. The predicted and NCPA-reported percentages of prescriptions by payer were, respectively, 23.7% and 24% for Part D, 11.6% and 9% for cash, 56.6% and 52% for private third party, and 8.1% and 15% for Medicaid. While this discrepancy may appear to be a significant limitation, it is probably not reasonable to expect that the 2 sources would provide the same estimates. The model assumed that the only change in the pharmacy environment between 2005 and 2006 was the implementation of Part D. The NCPA estimates, which are based on real-world data and conditions, reflected all changes in the pharmacy environment. These included, for example, changes in Medicaid eligibility requirements, changes in employers' willingness to offer private coverage for drugs, increases in patient cost sharing, changes in reimbursement rates of other third-party payers, and changes in competition such as the Wal-Mart $4 generic program.
As discussed in the Methods section, the model assumed that no Part D prescriptions for Medicaid patients would be dispensed through mail-order pharmacies. To the extent that Medicaid patients did use mail-order pharmacies, the negative effects on pharmacy profitability would be larger than estimated by the model. However, given the historically low use of mail order in public insurance programs 22 and the lower copayments charged to Medicaid patients (compared with non-Medicaid patients) in Part D plans, 28 it seems unlikely that mail-order use would constitute a sizeable proportion of total Part D utilization by Medicaid patients.
■■ Conclusions
A financial model based on a national sample of independent community pharmacies indicated that Part D has had a substantial and negative effect on the profitability of community pharmacies. This outcome has resulted primarily from the lower reimbursement rates that pharmacies receive for Part D prescriptions. However, the typical pharmacy remained profitable even in the worst case scenario.
